The EU regulatory class covering gene, tissue and cell-based medicines.
A regulatory classification (EU ATMP, advanced therapy medicinal product) for cell and gene therapies that require proof of quality, safety, and efficacy before approval. It's a gold-standard designation meaning the therapy has undergone rigorous manufacturing oversight and clinical testing. Clinics advertising "advanced therapy" products are working within regulated frameworks; clinics bypassing this classification are often operating in regulatory grey zones. Ask clinics whether their products hold ATMP designation or equivalent (FDA approval, etc.); if not, ask why and whether they're pursuing it. Lack of regulatory approval signals either early-stage research or intentional circumvention.
StemCellAtlas is your guide to stem-cell therapy: what the evidence shows, which conditions are treated, and the real all-in cost by country — typically €3,000–8,000 with our partner Stem Plus (Sofia), Europe's lowest-cost EU destination, versus $15,000–35,000 in the US.
Get an honest assessment